Carol Dobrzynski
Child & Adolescent Psychiatry · Brick, NJNPI 1255407367
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 642 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. Among child & adolescent psychiatry clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 642 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$998
- Takeda Pharmaceuticals U.S.A., Inc.$859
- Supernus Pharmaceuticals, Inc.$690
- Axsome Therapeutics, Inc.$624
- plus $3K from 25 others
What the payments were for
- Food & beverage$9,68099%
- Education$791%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 90 | $1,999 |
| AbbVie(2 entities) | 128 | $1,349 |
| Otsuka America Pharmaceutical, Inc. | 59 | $998 |
| Takeda Pharmaceuticals U.S.A., Inc. | 64 | $859 |
| Supernus Pharmaceuticals, Inc. | 41 | $690 |
| Axsome Therapeutics, Inc. | 27 | $624 |
| Sunovion Pharmaceuticals Inc. | 38 | $460 |
| Ironshore Pharmaceuticals Inc. | 29 | $381 |
| Vanda Pharmaceuticals Inc. | 19 | $284 |
| Tris Pharma Inc | 19 | $265 |
| Johnson & Johnson | 14 | $205 |
| Bausch Health US, LLC | 14 | $196 |
| Neos Therapeutics, LP | 14 | $194 |
| Collegium Pharmaceutical, Inc. | 11 | $149 |
| Eisai Inc. | 9 | $125 |
| Corium, LLC | 10 | $124 |
| Alkermes, Inc. | 6 | $93 |
| Harmony Biosciences LLC | 4 | $92 |
| Teva Pharmaceuticals USA, Inc. | 2 | $83 |
| Avanir Pharmaceuticals, Inc. | 6 | $79 |
| Almatica Pharma LLC | 5 | $71 |
| Shire North American Group Inc | 5 | $68 |
| Jazz Pharmaceuticals Inc. | 5 | $68 |
| Lundbeck LLC | 5 | $59 |
| OWP Pharmaceuticals, Inc. | 4 | $59 |
| Adlon Therapeutics L.p. | 4 | $54 |
| Noven Therapeutics, LLC | 3 | $47 |
| Rhodes Pharmaceuticals L.p. | 3 | $37 |
| Vertical Pharmaceuticals, LLC | 2 | $23 |
| Merck | 1 | $12 |
| Neurocrine Biosciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$837
- REXULTI$125
- Auvelity$125
- ABILIFY MAINTENA$114
How this compares
$9,760 in reported general payments places this provider in the 90th percentile of 137 child & adolescent psychiatry providers in New Jersey.
See all child & adolescent psychiatry providers in New Jersey →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 30 | $56,970 |
| FanaptIloperidone | 16 | $41,944 |
| RexultiBrexpiprazole | 12 | $39,260 |
| AplenzinBupropion Hbr | 12 | $31,307 |
| VraylarCariprazine Hcl | 14 | $24,050 |
| VyvanseLisdexamfetamine Dimesylate | 21 | $10,512 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 45 | $5,235 |
| Atomoxetine Hcl | 14 | $4,536 |
| DayvigoLemborexant | 12 | $4,079 |
| Vilazodone Hcl | 39 | $3,921 |
| Bupropion XlBupropion Hcl | 138 | $3,327 |
| Buspirone Hcl | 122 | $3,112 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 42 | $2,935 |
| Duloxetine Hcl | 139 | $2,579 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 28 | $2,536 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,999 | $56,97030 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $284 | $41,94416 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $998 | $39,26012 claims |
| Bausch Health US, LLCAplenzin | $196 | $31,30712 claims |
| AbbVieVraylar | $1,349 | $24,05014 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $859 | $10,51221 claims |
| Eisai Inc.Dayvigo | $125 | $4,07912 claims |
| Almatica Pharma LLCSertraline Hcl | $71 | $1,414100 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 137 child & adolescent psychiatry providers in New Jersey.
Other child & adolescent psychiatry in Brick
- Ravinder BhallaRidgewood$125K
- Steven DyckmanEast Brunswick$53K
- Eric BartkyLivingston$51K
- Bohdan CzartoryskyParsippany$21K
- Akhtar HossainSomerville$19K
- Suzanne LindNew Brunswick$18K
- Aykut OzdenEdgewater$17K
- Valeria KorshunovaHackensack$12K
- Saranga BhallaPrinceton$5K
- Tahir KhwajaNorth Brunswick$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.